Actolind (06.3637. Actolind Gel Plus)
ACTO GmbH · Decision date Sep 22, 2026
What did the FDA decide?
ACTO GmbH received FDA 510(k) clearance K254168 on September 22, 2026, for Actolind® Gel Plus, a clear, colorless hydrogel whose basis formulation includes Poloxamer 188, monopropylene glycol, hydroxypropyl guar, ammonium lactate, ColaLipid C and purified water, with polyhexamethylenebiguanide HCl at 0.1% w/w as a preservative. The decision was substantially equivalent (SESE), which is a marketing clearance, not a premarket approval. The submission was received December 23, 2025, and the product code is FRO; the FDA page lists the classification name as Dressing, Wound, Drug and the review panel as General & Plastic Surgery.
The summary names Prontosan Wound Gel (B. Braun Medical, K163430, May 23, 2017) as the predicate and states that the chemical-formula differences raise no new or different questions of safety or effectiveness. The indications cover over-the-counter use on minor cuts, abrasions, lacerations and burns, and professional use on ulcers, first- and superficial partial-thickness burns, partial and full thickness wounds, large surface area wounds and surgical incisions. The summary reports ISO 10993 biocompatibility testing and limits use to under 24 hours. The specialty field is recorded as unknown, and no clinical outcome data are provided.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Unknown
- Decision date
- Sep 22, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254168
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- ACTO GmbH
- Product code
- FRO
- Decision code
- SESE
- Decision date
- Sep 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Dressing, Wound, Drug.
FDA decision timeline
K254168 received
Application receipt date recorded by FDA.
K254168 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code FRO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Coloplast Corp. | 510(k) clearance | Oct 26, 2026 | FDA | |
| Magic Science Supply, LLC | 510(k) clearance | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ACTO GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Braunschweig
Sources and methodology
- Original FDA record: K254168
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
